Skip to content

Inspection Record

Aeon Biotherapeutics Corp. — FDA 483 Findings

US FDAInspected 2025-03-07Published 2026-10-21 4 findingsOther quality systemEquipment and facility

Inspectors Creighton T Tuzon · Nisha C PatelThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

Products that do not conform to specifications are not adequately controlled.

2Equipment and facility

Procedures to prevent contamination of equipment or product by substances that may have an adverse effect on product quality have not been adequately established.

3Other quality system

Procedures foM of nonconforming product have not been adequately established.

4Other quality system

Procedures for corrective and preventive action have not been adequately established.

A record as of the US FDA document published on 2026-10-21. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Aeon Biotherapeutics Corp. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.